{"name":"CytomX Therapeutics","slug":"cytomx","ticker":"CTMX","exchange":"NASDAQ","domain":"cytomx.com","description":"CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pip","hq":"South San Francisco, CA","founded":0,"employees":"69","ceo":"Sean McCarthy","sector":"Oncology Biotech","stockPrice":3.73,"stockChange":-0.06,"stockChangePercent":-1.58,"marketCap":"$813M","metrics":{"revenue":76201000,"revenueGrowth":-79.9,"grossMargin":100,"rdSpend":68728000,"netIncome":-17368000,"cash":346707008,"dividendYield":0,"peRatio":-7.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"CX-072 patent cliff ($0.0B at risk)","drug":"CX-072","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"CX-2009 patent cliff ($0.0B at risk)","drug":"CX-2009","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"CytomX Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CX-2009","summary":"CytomX Therapeutics announced that the FDA has cleared the IND application for CX-2009, a Prostate-Specific Membrane Antigen (PSMA)-targeting antibody-drug conjugate.","drugName":"CX-2009","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"CytomX Therapeutics Reports Third Quarter 2023 Financial Results","summary":"CytomX Therapeutics reported its third quarter 2023 financial results, with a net loss of $23.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"CytomX Therapeutics Announces Collaboration with Bristol Myers Squibb to Develop Cancer Therapies","summary":"CytomX Therapeutics announced a collaboration with Bristol Myers Squibb to develop cancer therapies, including a prostate cancer treatment.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-20","type":"trial","source":"simplywall.st","summary":"How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data - simplywall.st","headline":"How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNTXZBZmRERGlQWVBSTmU5LUZnSkRIUW5hZURjZnBrYjlvS2g2dmxIRnpxZjVSY2lMRlVka2k3Q2pLdW1FblllNDhsRWlfbVBLVHBHNnNkYkE3Z2pzQlNDT2NWMkZlX2NZVU1lbk1IdTVhSWk5MFBqamhIUEtxaUtLcl95YnBGTG9WUjZhaUVTUGhfMm5BMlZGQ1JhSFFDZ0FabUF4Tk9BWWhjd3NXU0pBUDFCZi0?oc=5","date":"2026-03-19","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Thursday's Intraday Session","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-17","type":"trial","source":"simplywall.st","summary":"A Look At CytomX Therapeutics (CTMX) Valuation After Varseta M Phase 1 Expansion Data And Earnings Update - simplywall.st","headline":"A Look At CytomX Therapeutics (CTMX) Valuation After Varseta M Phase 1 Expansion Data And Earnings Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNdW9uOFpuQUxrU2dWV0tNVUh4dl9xZkM4S2FPSWtzYl8wV0RNUjdCa2ZrQzlSYUFfNjhIY2VKU0RBTFNaZ1o5eG1GQ2dsR2E0UjJfcERqejlfOHZJZ0M2c2JoQTc2a1U3bm5QZmJza3NIVnFuX2hVVlN6VmFWMHlNQWFvYzJDWlhVT3RCREs5VGZJdTNTaElzOXh3N1I4TDVkQkM1Tnc0cE5yNk1OR251RFFpeUZMZ2hpM1RtN0N0SllPb0xTLVVTSGRDM192UGpOWTluT093VVRLT1RzcDRmY3dVdw?oc=5","date":"2026-03-17","type":"trial","source":"The Globe and Mail","summary":"CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail","headline":"CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPOEVfLU8zSUlsNGtzODR5VkRaR082WGRfR3VfTTBDNDV5dVg1OUdncFlWRTlPZ21IZmtSNjdHVWdTZm41QUhlaG8xalliZjJPSXNGR01JdGpfRHBiWm5OTFN2dDZkNXlWZ3BPeW0wZ2FwZzFVNEpYZFVZSnE4X0JRZWxlNktOZWI5Y2ZBUGM3ajlZajZkalVYeExPYTRJajNtVWhCVWNNQkdPYjAtWW10VVRfdzk2bG1JLThnLXhBMkZOcEdtSkNLOVUyOEI?oc=5","date":"2026-01-19","type":"pipeline","source":"AD HOC NEWS","summary":"CytomX Therapeutics Is Going Wild: Is CTMX the Next Biotech Rocket or Just Hype? - AD HOC NEWS","headline":"CytomX Therapeutics Is Going Wild: Is CTMX the Next Biotech Rocket or Just Hype?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQeXZ6SnJKRElYd0VkdUpkaF9lc3U5dzlJQ1FDRmN2eU9lT2s4OXQyZTVCY0x6ODVWZDhqZnhhMmZXblVNZFZmcGgxcFByUGk3UzVKQ0NLX212djkzanBmM3R5QklDYU5nYXpQQ0hxMFhHcFAyR3lJaVVMNThsc291WjQtZDRhWVBPLUV3Q2FBS3c0NkxJb1ltQ3dMZ1pVbV9aN3hQYzJQcXc?oc=5","date":"2026-01-05","type":"pipeline","source":"investingnews.com","summary":"Top 5 Small-cap Pharma Stocks (Updated January 2026) - investingnews.com","headline":"Top 5 Small-cap Pharma Stocks (Updated January 2026)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-13","type":"pipeline","source":"simplywall.st","summary":"Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically - simplywall.st","headline":"Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE8tU2I0QW5iLVVMTFliNE5MekNWWjRtRU9IRVJfa3lpRXh4aE9uZXZKd3RNT2c3dDVEYzZONWxRY21zdnA5bFRlZXpqa1dLTFNMV1h3?oc=5","date":"2025-08-13","type":"trial","source":"firstwordpharma.com","summary":"CytomX continues Phase I ADC study after patient death - firstwordpharma.com","headline":"CytomX continues Phase I ADC study after patient death","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBoY3dndzhoOHZNQlpmbmhJVHUxcW1IWXg5N296T2tzYUhpYUdzby1CSXVsSl91R3JIZm11V1BXNFFXRl9UTDlsdklfeFgxNTNyajd0QTVBWTdXaTF1RWRNSjdCbDhPSV9f?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"CytomX Therapeutics (CTMX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"CytomX Therapeutics (CTMX) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-06-18","type":"pipeline","source":"simplywall.st","summary":"Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching - simplywall.st","headline":"Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9MVTVwWHRUa2FfX1hrWDQySVRlZ3RUNWd2OEUtZTFKalRWZVdGMVlrNkR2VHljVklscUVYZGZUTlB3bVVnSV9Qb3BCQW9NcGhp?oc=5","date":"2024-03-26","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOZFBWTWplT3hRcDZLcUNnaGV1czRWZUFoOGFud3Fwc01peHlpVloyTHRxSHJMMU8tYzAyM3JvSVI3NmxaeGt1MkpiU0JOdzhTQTVrSVN5YWVNb0E3LVFua3EtNVFDY1NHM1FLMUtSVmJaa0drbE9FazVLNG5fTFF0OU85RndGWThGSnJnb1cwQUhJaHNtc0RCbkdXWQ?oc=5","date":"2022-11-17","type":"pipeline","source":"The Pharma Letter","summary":"CytomX to earn up to $2 billion in Regeneron tie-up - The Pharma Letter","headline":"CytomX to earn up to $2 billion in Regeneron tie-up","sentiment":"neutral"}],"patents":[{"drugName":"CX-072","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"CX-2009","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Cancer"],"financials":{"source":"sec_edgar+yahoo","revenue":76201000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":76201000,"period":"2025-12-31"},{"value":138103000,"period":"2024-12-31"},{"value":138103000,"period":"2024-12-31"},{"value":101214000,"period":"2023-12-31"},{"value":101214000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":68728000,"rdSpendHistory":[{"period":"2025-12-31","value":68728000},{"period":"2024-12-31","value":83382000},{"period":"2023-12-31","value":77680000},{"period":"2022-12-31","value":111649000}],"sgaSpend":29837000,"operatingIncome":-22364000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-22364000},{"period":"2024-12-31","value":24995000},{"period":"2023-12-31","value":-6484000},{"period":"2022-12-31","value":-101335000}],"netIncome":-17368000,"netIncomeHistory":[{"period":"2025-12-31","value":-17368000},{"period":"2024-12-31","value":31869000},{"period":"2023-12-31","value":-569000},{"period":"2022-12-31","value":-99317000}],"eps":0.38,"epsHistory":[{"period":"2024-12-31","value":0.38},{"period":"2023-12-31","value":-0.01},{"period":"2022-12-31","value":-1.51},{"period":"2021-12-31","value":-1.3}],"cash":12667000,"cashHistory":[{"period":"2025-12-31","value":12667000},{"period":"2024-12-31","value":38052000},{"period":"2023-12-31","value":17171000},{"period":"2022-12-31","value":193650000}],"totalAssets":151566000,"totalLiabilities":52558000,"totalDebt":4240000,"equity":99008000,"operatingCashflow":-75587000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-75587000},{"period":"2024-12-31","value":-86231000},{"period":"2023-12-31","value":-56035000},{"period":"2022-12-31","value":-110788000}],"capex":-220000,"capexHistory":[{"period":"2025-12-31","value":-220000},{"period":"2024-12-31","value":-310000},{"period":"2023-12-31","value":-840000},{"period":"2022-12-31","value":-1740000}],"freeCashflow":-75807000,"dividendsPaid":null,"buybacks":null,"employees":69,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":7360000,"ebit":-27932000,"ebitda":-27422000,"period":"2025-12-31","revenue":663000,"epsBasic":null,"netIncome":-26510000,"rdExpense":21235000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-27932000},{"sga":6427000,"ebit":-15768000,"ebitda":-15634000,"period":"2025-09-30","revenue":5963000,"epsBasic":-0.09,"netIncome":-14229000,"rdExpense":15304000,"epsDiluted":-0.09,"grossProfit":null,"operatingIncome":-15768000},{"sga":6622000,"ebit":-1286000,"ebitda":-939000,"period":"2025-06-30","revenue":18658000,"epsBasic":0,"netIncome":-154000,"rdExpense":13322000,"epsDiluted":0,"grossProfit":null,"operatingIncome":-1286000},{"sga":9428000,"ebit":22621000,"ebitda":23006000,"period":"2025-03-31","revenue":50917000,"epsBasic":0.27,"netIncome":23525000,"rdExpense":18868000,"epsDiluted":0.27,"grossProfit":null,"operatingIncome":22621000},{"sga":5624000,"ebit":17679000,"ebitda":18092000,"period":"2024-12-31","revenue":38093000,"epsBasic":null,"netIncome":18876000,"rdExpense":14790000,"epsDiluted":null,"grossProfit":null,"operatingIncome":17679000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":0.07,"netIncome":null,"rdExpense":null,"epsDiluted":0.07,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.73,"previousClose":3.79,"fiftyTwoWeekHigh":8.21,"fiftyTwoWeekLow":1.72,"fiftyTwoWeekRange":"1.72 - 8.21","fiftyDayAverage":4.51,"twoHundredDayAverage":3.9,"beta":0,"enterpriseValue":481243072,"forwardPE":-7.5,"priceToBook":2.54,"priceToSales":22.88,"enterpriseToRevenue":13.54,"enterpriseToEbitda":-7.94,"pegRatio":0,"ebitda":-60615000,"ebitdaMargin":-170.5,"freeCashflow":-44605624,"operatingCashflow":-80093000,"totalDebt":2856000,"debtToEquity":0.9,"currentRatio":10.38,"returnOnAssets":-16.9,"returnOnEquity":-34.3,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":13,"targetHighPrice":16,"targetLowPrice":11,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.6,"institutionHeldPercent":81.3,"sharesOutstanding":217702919,"floatShares":189464673,"sharesShort":29742798,"shortRatio":6.95,"shortPercentOfFloat":13.7,"epsTrailing":-0.52,"epsForward":-0.5,"revenuePerShare":0.22,"bookValue":1.47,"officers":[{"age":58,"name":"Dr. Sean A. McCarthy DPHIL","title":"Chairman & CEO"},{"age":41,"name":"Mr. Christopher W. Ogden","title":"SVP, CFO & Secretary"},{"age":47,"name":"Ms. Rachael  Lester","title":"Chief Business Officer & Senior VP"},{"age":58,"name":"Dr. Marcia P. Belvin Ph.D.","title":"Senior VP & Chief Scientific Officer"},{"age":68,"name":"Mr. Lloyd A. Rowland Jr., J.D.","title":"Senior VP, General Counsel, Chief Compliance Officer & Secretary"},{"age":null,"name":"Ms. Danielle  Olander-Moghadassian","title":"Senior VP & Chief Human Resources Officer"},{"age":null,"name":"Ms. Leslie  Robbins J.D.","title":"Senior Vice President of Intellectual Property"},{"age":57,"name":"Dr. Yu-Waye  Chu M.D.","title":"Senior VP & Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.cytomx.com","phone":"650 515 3185"}}